Loebsack diabetes legislation on way to president
Act aims to streamline federal investments, improve care
CEDAR RAPIDS — Legislation co-sponsored by Iowa 2nd District Democratic Rep. Dave Loebsack to coordinate a national response to diabetes has been approved and is headed to President Donald Trump for his signature.
The National Clinical Care Commission Act will improve the federal response to diabetes and other metabolic and autoimmune diseases by establishing a private-public commission to make recommendations to streamline federal investments, as well as improve coordination and clinical care outcomes, according to Loebsack.
The Iowa City Democrat co-sponsored the House version of the bill with Texas Rep. Pete Olson. It passed by unanimous consent on a voice vote.
“The passage of the National Clinical Care Commission Act will help the nation undertake a more proactive and innovative approach to diabetes, for which the United States spends $322 billion annually,” said Loebsack.
The commission will bring together clinical endocrinologists, specialists, health care professionals, patients and representatives from the federal agencies. It is charged with identifying where new approaches are needed to improve diabetes care, eliminating duplication, assisting in coordination across all federal agencies, leveraging federal investment in public health by evaluating best practices, evaluating the utilization and data collection mechanisms of existing programs and providing guidance on diabetes clinical care.